Axsome Therapeutics, Inc. (AXSM) Cash Flow Statement
Axsome Therapeutics, Inc. (AXSM) generated -$71.3M of operating cash flow over the twelve months to 2026-06-30, spent $700000 on capital expenditure and had free cash flow of -$72.0M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AXSMAxsome Therapeutics, Inc.Follow AXSM — free
—
Price chart with a free account
- Market cap
- 7.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Operating cash flow | -116.5 | -145.1 | -128.4 | -93.4 | -71.3 | |
| Capital expenditure | 0.7 | 0.6 | 0.3 | 0.5 | -0.7 | |
| Free cash flow | -117.2 | -145.7 | -128.7 | -93.9 | -72.0 | |
| Stock-based compensation | 37.7 | 62.6 | 85.2 | 93.8 | — |
USD millions · SEC XBRL
Axsome Therapeutics, Inc. — questions
- What is Axsome Therapeutics, Inc.'s operating cash flow?
- -$71.3M over the twelve months to 2026-06-30.
- How much does Axsome Therapeutics, Inc. spend on capital expenditure?
- $700000 over the twelve months to 2026-06-30.
- What is Axsome Therapeutics, Inc.'s free cash flow?
- -$72.0M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Axsome Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.